A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Doctors are testing a new medicine called AMG 701 to see if it's safe and how much of it people can take. They are studying it in adults who have a type of cancer called multiple myeloma that has come back after treatment. They will also be testing how well the medicine works when combined with other treatments. This study will help doctors figure out if AMG 701 could be a good treatment for this cancer.
Doctors are testing a new medicine called AMG 701 to see if it's safe and how much of it people can take. They are studying it in adults who have a type of cancer called multiple myeloma that has come back after treatment. They will also be testing how well the medicine works when combined with other treatments. This study will help doctors figure out if AMG 701 could be a good treatment for this cancer.
*Third Opinion AI Generated Synopsis
Trial Summary
The primary purpose of the phase 1 part of the study is to evaluate safety and tolerability of AMG 701 monotherapy to identify the RP2D for AMG 701 monotherapy followed by a dose-confirmation part to gather further safety data for AMG 701 monotherapy at the RP2D in adult subjects with relapsed/refractory multiple myeloma (RRMM). In addition, this study will include a sequential dose exploration part to identify the RP2D of AMG 701 in combination with pomalidomide, with and without dexamethasone (AMG 701-P+/-d). Phase 2 will consist of the dose-expansion part to gain further efficacy and safety experience with AMG 701 monotherapy in adult subjects with RRMM.
The primary purpose of the phase 1 part of the study is to evaluate safety and tolerability of AMG 701 monotherapy to identify the RP2D for AMG 701 monotherapy followed by a dose-confirmation part to gather further safety data for AMG 701 monotherapy at the RP2D in adult subjects with relapsed/refractory multiple myeloma (RRMM). In addition, this study will include a sequential dose exploration part to identify the RP2D of AMG 701 in combination with pomalidomide, with and without dexamethasone (AMG 701-P+/-d). Phase 2 will consist of the dose-expansion part to gain further efficacy and safety experience with AMG 701 monotherapy in adult subjects with RRMM.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.